Perrigo closes two plants
The private labeler is closing its Holland and Montague, Mich.-based manufacturing facilities and will "transfer its profitable product lines" from those locations to plants based in Allegan, Mich. and The Bronx, N.Y., Perrigo announces June 27. The firm will discontinue production for its unsuccessful psyllium-based laxatives and effervescent tablets. The closings correspond with Perrigo's business strategy to improve efficiency and successfully integrate Agis, an Israeli generics firm acquired in March 2005, the firm states. Perrigo estimates an $8 mil. pre-tax charge will be incurred during Q4 2006 (ending July 1) as well as a $3 mil. one-time cost during fiscal 2007 as a result of the plant closings. All 140 employees affected by the closing plants will be offered positions at the Allegan site, Perrigo says...
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
Rexulti’s post-traumatic stress disorder sNDA tries to make up for a failed Phase III study by placing a Phase II study into a key evidentiary role, raising questions for the July 18 advisory committee meeting about assessing discordant results and post-hoc analyses.
The FDA is pushing the use of novel alternatives to animal models, but the Government Accountability Office said sponsors need more clarity and hopes an upcoming guidance will help.
The Association of the British Pharmaceutical Industry says that while the government’s newly published Life Sciences Sector Plan includes many positive commitments, they are not enough.